NEDD8 and cancer: These data suggested the NEDD8 pathway as a promising therapeutic target and MLN4924/Pevonedistat is in Phase II cancer clinical trials10, https://clinicaltrials.gov/ct2/show/NCT02610777?term=pevonedistat&rank=1).